Mabwell Stocks

Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.